In addition, FXR‐α activity was shown to suppress NF‐κB agonist‐induced inflammatory gene expression in an FXR‐α‐dependent manner in HepG2 cells and mouse primary hepatocytes60 as well as CRP release,61 suggesting that blocking IL‐1R1 in hepatocytes prevents dysregulation of both PGC‐1α and FXR‐α in NAFLD. Here, IL1R1 is linked to metabolic dysfunction-associated steatotic liver disease.